Major Banks Adjust Price Targets for GEHC, WEC, and DexCom

Key Facts

As analysts refine valuation models heading into the third quarter, several major firms have seen adjustments to their price targets based on current market dynamics. UBS lowered its price target for GE Healthcare Technologies (GEHC) to $67 from $69 while maintaining a Neutral rating, whereas JPMorgan increased its target for WEC Energy Group (WEC) to $124 from $120. In the medical device sector, Truist raised its price target for DexCom (DXCM) to $87 from $80, reaffirming a Buy recommendation.

These adjustments arrive as healthcare stocks experience performance fluctuations; DXCM closed at $72.73 and GEHC at $63.20 per market data on July 15, 2026. In comparison to peers, the utilities sector shows relative stability, with WEC closing at $112.97 on the same date, influenced by interest rate expectations that typically impact yield-heavy stocks. According to recent sector earnings reports, the market focus remains on operating margins and the ability of firms to withstand cost pressures.

Investors should monitor current support levels, as GEHC trades near its July 15 low of $61.79, while WEC shows resilience above the $112 level. Looking at the economic calendar, there are no direct catalysts for these specific instruments in the coming seven days; however, broader market sentiment may be influenced by recent macro data, requiring close observation of price reactions to these new targets following the mid-July closing levels.